Combined company to operate as Coeptis
Therapeutics Holdings, Inc. and commence trading on The Nasdaq
Global Market under Ticker Symbol "COEP"
WEXFORD,
Pa. and MIAMI,
Oct. 31,
2022 /PRNewswire/ -- Coeptis Therapeutics, Inc.
("Coeptis"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, today announced the completion of its
business combination with Bull Horn Holdings Corp. (Nasdaq: BHSE),
a special purpose acquisition company ("Bull Horn"). In
connection with the Business Combination, the combined company has
been renamed "Coeptis Therapeutics Holdings, Inc." (the "Company")
and its public shares and warrants are expected to commence trading
on the Nasdaq Global Market under the ticker symbols "COEP" and
"COEPW," respectively, today, October
31, 2022. The Company will continue to focus primarily
on the development of innovative cell therapy platforms for
patients with cancer.
In connection with the Business Combination, the former
stockholders of Coeptis exchanged their shares of common stock for
common stock of Bull Horn at a rate of 2.96851721 for 1.
Following the Business Combination, the Company has approximately
19.5 million shares of common stock issued and outstanding, with
the former stockholders of Coeptis now owning approximately 88% of
the Company, and the existing shareholders of Bull Horn owning
approximately 12% of the Company.
"This is a significant step for Coeptis as we seek to become a
leader in the development of next generation cell therapy
technologies for cancer. This transaction closely follows our
recent in-licensing of SNAP-CAR, a multi-antigen CAR T technology
platform, providing a springboard into what we envision will be an
active period for the company," said David
Mehalick, who will lead the Company as Chief Executive
Officer and Chairman. "Critically important, the merger with Bull
Horn has enabled our stock to be listed on the Nasdaq Global
Market. Uplisting to Nasdaq is a key aspect of our goal to
drive long-term shareholder value by potentially augmenting our
visibility within the investment community to increase the
liquidity of our stock and broaden our shareholder base."
Following the closing of the Business Combination, David Mehalick will serve as the Chief Executive
Officer and Chairman, and the remaining Coeptis executive team will
continue with the Company in the roles they served at Coeptis prior
to the Business Combination. Christopher
Calise, Bull Horn's Chief Financial Officer and Director,
will serve on the Board of Directors of the Company.
In light of the closing of the Business Combination, Bull Horn
has cancelled its special meeting of shareholders that had been
previously scheduled for November 2,
2022, to vote on an amendment to its amended and restated
memorandum and articles of association to extend the deadline to
complete Bull Horn's initial business combination.
Advisors
Ellenoff Grossman & Schole LLP acted as
legal advisor to Bull Horn, and Meister
Seelig & Fein LLP acted as legal advisor to Coeptis.
JonesTrading Institutional Services LLC provided capital markets
advisory services to Bull Horn, and Bridgeway Capital Partners
advised Coeptis about the Business Combination.
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., is a biopharmaceutical company developing innovative cell
therapy platforms for cancer that have the potential to disrupt
conventional treatment paradigms and improve patient outcomes. The
Company's product portfolio and rights are highlighted by a
universal, multi-antigen CAR T technology licensed from the
University of Pittsburgh (SNAP-CAR),
and a cell therapy technology (CD38-GEAR-NK) and an in vitro
diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which
the Company is developing with VyGen-Bio and leading medical
researchers at the Karolinska
Institutet. The Company's business model is designed around
maximizing the value of its current product portfolio and rights
through in-license agreements, out-license agreements and
co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings,
specifically those targeting cancer. The Company was founded in
2017 and is headquartered in Wexford,
PA. For more information about the Company, please visit
https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking
Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to obtain or maintain the listing of the Company's securities on
the Nasdaq Global Market following the Business Combination; (2)
the risk that the Business Combination disrupts current plans and
operations of Coeptis as a result of the consummation of the
Business Combination; (3) the inability to recognize the
anticipated benefits of the Business Combination, which may be
affected by, among other things, competition, the ability of the
Company to grow and manage growth economically and hire and retain
key employees; (4) the risks that Coeptis' products in development
fail clinical trials or are not approved by the U.S. Food and Drug
Administration or other applicable regulatory authorities; (5)
costs related to the Business Combination; (6) changes in
applicable laws or regulations; (7) the possibility that the
Company may be adversely affected by other economic, business,
and/or competitive factors; and (8) the impact of the global
COVID-19 pandemic on any of the foregoing risks and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission (the "SEC"). The foregoing list
of factors is not exclusive. All forward-looking statements are
subject to significant uncertainties and risks including, but not
limited, to those risks contained or to be contained in reports and
other filings filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings made or
to be made with the SEC, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise
these forward–looking statements to reflect events or circumstances
that arise after the date hereof unless required by applicable
laws, regulations or rules.
CONTACTS
Coeptis Therapeutics Holdings,
Inc.
Investors
Tiberend Strategic Advisors,
Inc.
Jon Nugent
jnugent@tiberend.com
Media
David
Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-inc-announces-closing-of-business-combination-with-bull-horn-holdings-corp-301662851.html
SOURCE Coeptis Therapeutics